GlassScriptPhysician profile
Anthony Accurso
NPI 1295098424
$5,177.47
in general payments reported to CMS, 2019-2025
54 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $333 · 2021: $39.33 · 2022: $546 · 2023: $1,261 · 2024: $1,377 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $624.24 | 2019-2025 | |
| Pfizer INC. | $604.53 | 2019-2025 | |
| Celgene Corporation | $348.48 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $325.15 | 2019-2025 | Imfinzi |
| Janssen Biotech, INC. | $271.56 | 2019-2024 | Erleada, Balversa, Akeega |
| E.R. Squibb & Sons, L.L.C. | $264.78 | 2019-2024 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $243.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $213.22 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $137.46 | 2019-2023 | Tukysa |
| Genentech USA, INC. | $120.36 | 2022-2023 | Tecentriq |
| Array Biopharma INC | $120.30 | 2022-2024 | Braftovi, Lorbrena, Mektovi |
| Lilly USA, LLC | $113.75 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Genzyme Corporation | $103.76 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.72 | 2023-2024 | Alunbrig, Fruzaqla, Ninlaro |
| Abbvie INC. | $91.39 | 2024-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Accurso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.